Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $6.4 million.

  • Cumberland Pharmaceuticals' Other Operating Expenses fell 539.21% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 1120.29%. This contributed to the annual value of $475000.0 for FY2023, which is N/A changed from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Other Operating Expenses stood at $6.4 million for Q3 2025, which was down 539.21% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Other Operating Expenses registered a high of $10.8 million during Q4 2023, and its lowest value of $6.1 million during Q3 2021.
  • Its 5-year average for Other Operating Expenses is $7.4 million, with a median of $7.2 million in 2025.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Other Operating Expenses surged by 6689.93% in 2023, and later crashed by 2927.4% in 2024.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Other Operating Expenses stood at $7.6 million in 2021, then decreased by 15.17% to $6.5 million in 2022, then skyrocketed by 66.9% to $10.8 million in 2023, then decreased by 29.27% to $7.7 million in 2024, then decreased by 16.01% to $6.4 million in 2025.
  • Its Other Operating Expenses stands at $6.4 million for Q3 2025, versus $7.2 million for Q2 2025 and $6.7 million for Q1 2025.